The size of the Genetic Testing Market in Europe was worth USD 14.78 million in 2019 and is estimated to reach USD 23.29 Million by 2024 growing at a CAGR of 9.52% during the forecast period 2019 - 2024.
With the advancements in technology, healthcare facilities are also evolving increasing demand for superior medical care. Currently, genetic testing has been a highly attractive segment in the molecular diagnostics market owing to its ability to identify the slightest modification in chromosomes, genes, or proteins that are associated with inherited disease conditions.
Genetic testing is the analysis of genes, chromosomes, or proteins that helps to predict the risk of diseases, identify carriers of disease, diagnose diseases, or determine the likely course of a disease. Genetic testing has led to an easy diagnosis of diseases, such as sickle cell anemia, hemophilia, and cystic fibrosis, helping several patients in leading a normal life.
The primary reason behind the growth of the genetic testing market is the growing awareness lately among the individuals about its potentials. And also, an increase of research in the genetic testing space, aging population and rise of chronic disease cases, and growing incidences of cancer cases are the other factors contributing to the growth of the genetic testing market,
However, the costs associated with genetic testing are high and may hinder the growth of the market. And also, as there is no credible standard procedure for analysis, the individuals began to develop serious doubts concerning the authenticity of genetic reports, which negatively affects the market.
Genetic testing in cancer is anticipated to grow at a higher rate and likely to dominate the genetic testing market in the coming years. The market for screening the new-borns, diagnosing rare and fatal disorders, and estimating the probability of occurrence of diseases is likely to expand. Particularly, genetic tests to screen the new-borns are expected to expand immensely over the coming years.
The growing incidence of genetic diseases unravels new opportunities for genetic testing and its related applications. The transformation of genetic testing from being a service-driven market to a product-driven market is anticipated to provide a push to the diagnostic companies for the expansion of their operations.
The report has been segmented and sub-segmented into the following categories.
Some of the promising companies leading the Europe Genetic Testing Market profiled in this report are Abbott Laboratories, Roche Molecular Diagnostics Inc., Abbott Molecular Inc., AutoGenomics Inc., Celera Group, ELITech Group, BioRad Laboratories, PerkinElmer Inc., Roche Diagnostics Corp., Quest Diagnostics Inc., Transgenomic Inc. and Applied Biosystems Inc.,
This report comes with
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Prenatal Testing
5.1.4 Neonatal Testing
5.2 By Application
5.2.1 Cancer Testing
5.2.2 Prenatal Testing
5.2.3 Pharmacogenomics Testing
5.2.4 Presdisposition Testing
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Roche Molecular Diagnostics Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Abbott Laboratories
8.3 AutoGenomics Inc.
8.4 Celera Group
8.5 ELITech Group
8.6 BioRad Laboratories
8.7 Quest Diagnostics Inc
8.8 Transgenomic Inc.
8.9 Applied Biosystems Inc.,
8.10 PerkinElmer Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
